Thales’ FlytEDGE Digitally Remasters the inflight Entertainment Experience
28.5.2024 13:00:00 EEST | Business Wire | Press release
Thales unveils FlytEDGE, a revolutionary connected cloud-based inflight entertainment system that will transform passenger engagement to the extraordinary. FlytEDGE is not like a traditional IFE system — with a sleek architecture, cutting-edge features, and unparalleled performance it enables airlines to stand out by bringing the ‘cool’ factor to each seat, offering fully-tailored passenger interactions:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528532879/en/
(Photo: Thales)
- Live personalization for a journey filled with unique experiences
- Instantly stream favorites and never miss a beat, continue watching on all flights
- Immense volume of content to immerse passengers in a world of entertainment choices
Creating personalized experiences
Personalization is at the heart of FlytEDGE. Every passenger is one-of-a-kind and the system empowers airlines to recommend experiences tailored to each person's preferences. FlytEDGE is a true engagement platform offering boundless opportunities for connected and custom journeys. FlytEDGE delivers ‘just-for-you’ experiences never seen before. The system intelligently recommends content across domains, with an individually tailored and immersive entertainment experience.
Delivering the future of entertainment to each passenger
FlytEDGE is the IFEC industry’s first solution to feature edge caching. Passengers can now instantly stream their favorite entertainment using their personal video subscriptions and continue watching their favorite shows from the ground to the air and across flights.
Leveraging a state-of-the-art connected cloud architecture, the system breaks through barriers providing airlines with unparalleled flexibility to rapidly bring in any web-based service.
- Top game providers for interactive options that will captivate from take-off to touch down
- Video streamers that go beyond the blockbuster to bring infinite bingeable choices to passengers
With FlytEDGE airlines can integrate partners at the speed of consumer technology to create exhilarating experiences at the forefront of inflight entertainment.
Thales’ FlytEDGE solution features the best consumer technologies on the market. The system boasts cinematic 4K QLED HDR seatback displays to immerse passengers with over 1 billon vibrant colors and two Bluetooth® connections so passengers can pair their personal wireless devices. The system broadcasts the same user interface onboard for all devices- phones, tablets and seatback screens. With Thales’ Crystal Cabin® award-winning power solution delivering high-speed charging at each seat to any passenger device, everyone arrives at their destination recharged, entertained, and relaxed.
Value for airline customers
FlytEDGE features the Crystal Cabin® award-winning Onboard Data Center (ODC) with 96TB of storage to enable on-board edge caching, this solution reduces connectivity consumption and ensures bandwidth is available for other inflight services. No matter how many people watch the same content, each title streams once to the aircraft allowing passengers to instantly access endless entertainment.
The ODC takes the IFE system performance to new heights.
- Replaces the traditional multi-server network with an effective and compact blade architecture
- Simplifies upgradeability path with easy blade swaps
- Ensures the highest system availability
FlytEDGE goes beyond the hardware by redefining software and content updates to reduce cost and lead-time.
- Exceptional Efficiency – Remote operations with virtual labs for anywhere, anytime updates
- Superior Performance – Real-time system monitoring and automated maintenance tasks
- Scalable and Evolving – Continuous integration of new services for a system that is always growing at the speed of consumer technologies
FlytEDGE is already flying! We’re just at the beginning of what’s possible with a fully connected cloud platform. FlytEDGE’s game-changing features and intuitive functionality sets it light-years ahead of the competition. Bringing Thales’ FlytEDGE technology to the airline industry means an in-flight experience that is as eagerly awaited as the destination itself, and there’s so much more to look forward to. It is time to embrace the EDGE.
“At Thales we’re always at the forefront of innovation, investing in digital technologies, and working with our partners to redefine the inflight experience. We’re delighted to bring FlytEDGE’s state-of-the-art capabilities to our airline customers to create memorable and fully-tailored passenger interactions.” said Yannick Assouad, Executive Vice-President Avionics, Thales. “FlytEDGE is the first connected cloud-based IFE to introduce ground-breaking new experiences with a true engagement platform offering boundless opportunities for unique journeys. Stay tuned for more exciting news as the system is set to premier on a leading global airline.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Thales Group
Thales InFlyt Experience
X @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528532879/en/
Contact information
PRESS CONTACTS
Thales, Media Relations
Head of Media Relations, Aeronautics & Defense
Alice Pruvot
+33 (0)7 70 2711 37
alice.pruvot@thalesgroup.com
Thales, Media Relations
Civil Aeronautics
Chrystelle Dugimont
+33 (0)6 25 15 72 93
chrystelle.dugimont@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom